Search for: "Ortho McNeil Pharmaceutical Inc" Results 121 - 140 of 182
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
2 Jun 2011, 12:46 pm by Bexis
Ortho Pharmaceutical Corp., 681 P.2d 1038, 1052 (Kan. 1984). [read post]
23 Apr 2010, 8:20 am by Press Releases
” Expected to attend are IP leaders from BP America Inc., Merck & Co., Inc., Bose, Brigham Young University, Cornell University, Stanford University, Duke University, Georgetown University, GlaxoSmithKline, Honeywell, Harvard University, Johnson & Johnson, Kauffman Foundation, Lockheed Martin, Massachusetts Institute of Technology (MIT), Mayo Clinic, Ortho-McNeil Pharmaceuticals Inc., Rutgers, Syngenta Biotechnology, Scripps… [read post]
10 Jun 2009, 10:00 pm
Ortho-McNeil Pharmaceutical, 2007 WL 121149, at *4 (S.D. [read post]
18 Jan 2016, 5:00 am
Ortho-McNeil-Janssen Pharmaceuticals, Inc., 808 F.3d 281 (6th Cir. 2015) – preemption, but not involving generic drugs − which aptly described pre-approval theories as “never-start selling” claims (id. at 300), describes that other decision. [read post]
25 Aug 2011, 8:14 am by Lawrence B. Ebert
Bayer Schering, 575 F.3d at 1347 (citing O’Farrell, 853 F.2d at 903); see also Ortho-McNeil, 520 F.3d at 1364 (stating the number of options must be “small or easily traversed”). [read post]
25 Aug 2011, 8:14 am by Lawrence B. Ebert
Ortho-McNeil, 520 F.3d at 1364-65 (“[A] flexible TSM test remains the primary guarantor against a non-statutory hindsight analysis . . . . [read post]
22 Apr 2016, 12:51 pm
Ortho-McNeil-Janssen Pharmaceuticals, Inc., 808 F. 3d 281 (6th Cir. 2015); In re Celexa & Lexapro Marketing & Sales Practices Litigation, 779 F.3d 34 (1st Cir. 2015).Now there are three, and the latest is the most a fortiori of the lot.The Third Circuit has applied the Mensing/Bartlettimpossibility preemption rationale outside of the FDCA altogether, to preemption of design defect claims involving airplanes. [read post]
1 Jul 2009, 1:06 am
Levaquin, made by J&J subsidiary Ortho-McNeil Pharmaceutical Inc., was approved by the Food and Drug Administration in 1996, but in July 2008, the FDA warned that Levaquin, and other drugs in the fluoroquinolone class of antibiotics, put users at heightened risk of developing tendonitis and tendon ruptures. [read post]
3 Mar 2010, 5:05 am
(IP Osgoode) Australia: University of Western Australia’s application to appeal FCAFC’s decision in University of Western Australia v Gray fails (IP Whiteboard) Colombia/EU/Peru: Tough IP health provisions in Europe’s Colombia/Peru trade deal (IP Watch) (IP tango) EU: Something more about Swiss type claims: G02/08 (SiNApSE) (SiNApSE) US: Pharmaceutical patent settlements – and what about patients? [read post]
3 Mar 2010, 5:05 am
(IP Osgoode) Australia: University of Western Australia’s application to appeal FCAFC’s decision in University of Western Australia v Gray fails (IP Whiteboard) Colombia/EU/Peru: Tough IP health provisions in Europe’s Colombia/Peru trade deal (IP Watch) (IP tango) EU: Something more about Swiss type claims: G02/08 (SiNApSE) (SiNApSE) US: Pharmaceutical patent settlements – and what about patients? [read post]
13 May 2009, 1:31 am
Mass-Tort Treatment Sought for Suits Over Ortho-McNeil Antibiotic Levaquin New Jersey Law Journal Users of Levaquin, an antibiotic linked to muscle ailments, are asking the New Jersey Supreme Court to accord mass-tort treatment to their suits against the manufacturer, Johnson & Johnson subsidiary Ortho-McNeil Pharmaceutical. [read post]
7 Apr 2010, 4:30 am
Reddy's Laboratories, Ltd. et al (Docket Report) Retin-A Micro (Tretinoin) – US: District Court E D Texas: Promote Innovation files false marking complaint against Ortho-McNeil based on marking of Retin-A Micro product (Patent Docs) Seasonique (Levonorgestrel, Ethinyl estradiol) – US: Teva receives favourable court decision regarding Seasonique (SmartBrief) (The IP Factor) T2007 (Diphenyl barbituric acid) – US: Taro receives patent for new drug T2007 (The IP… [read post]